DE60039151D1 - Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen - Google Patents

Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen

Info

Publication number
DE60039151D1
DE60039151D1 DE60039151T DE60039151T DE60039151D1 DE 60039151 D1 DE60039151 D1 DE 60039151D1 DE 60039151 T DE60039151 T DE 60039151T DE 60039151 T DE60039151 T DE 60039151T DE 60039151 D1 DE60039151 D1 DE 60039151D1
Authority
DE
Germany
Prior art keywords
cells
cell
antibody
sign
clumping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039151T
Other languages
German (de)
English (en)
Inventor
Carl Gustav Figdor
Teunis Bernard Geijtenbeek
Kooyk Yvette Van
Ruurd Torensma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Original Assignee
Radboud Universiteit Nijmegen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radboud Universiteit Nijmegen filed Critical Radboud Universiteit Nijmegen
Application granted granted Critical
Publication of DE60039151D1 publication Critical patent/DE60039151D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
DE60039151T 1999-04-19 2000-04-19 Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen Expired - Lifetime DE60039151D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19990201204 EP1046651A1 (en) 1999-04-19 1999-04-19 Composition and method for modulating dendritic cell-T interaction
US17692400P 2000-01-20 2000-01-20
PCT/NL2000/000253 WO2000063251A1 (en) 1999-04-19 2000-04-19 Composition and method for modulating dendritic cell-t cell interaction

Publications (1)

Publication Number Publication Date
DE60039151D1 true DE60039151D1 (de) 2008-07-24

Family

ID=8240111

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60039151T Expired - Lifetime DE60039151D1 (de) 1999-04-19 2000-04-19 Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen
DE60044621T Expired - Lifetime DE60044621D1 (de) 1999-04-19 2000-04-19 Zusammensetzungen und Verfahren zur Modulierung der Interaktion zwischen dendritischer und T-Zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60044621T Expired - Lifetime DE60044621D1 (de) 1999-04-19 2000-04-19 Zusammensetzungen und Verfahren zur Modulierung der Interaktion zwischen dendritischer und T-Zellen

Country Status (13)

Country Link
US (4) US7148329B1 (enExample)
EP (3) EP1046651A1 (enExample)
JP (2) JP4989820B2 (enExample)
KR (3) KR100923340B1 (enExample)
AT (2) ATE472558T1 (enExample)
AU (1) AU776317B2 (enExample)
CA (1) CA2330231C (enExample)
DE (2) DE60039151D1 (enExample)
DK (2) DK1086137T3 (enExample)
ES (2) ES2346877T3 (enExample)
NZ (1) NZ508723A (enExample)
PT (2) PT1516881E (enExample)
WO (1) WO2000063251A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US6515124B2 (en) * 2000-02-09 2003-02-04 Hoffman-La Roche Inc. Dehydroamino acids
JP5007409B2 (ja) * 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US20040091481A1 (en) * 2000-12-21 2004-05-13 Figdor Carl Gustav Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
ES2197826B1 (es) * 2002-06-21 2005-04-01 Consejo Superior De Investigaciones Cientificas Compuesto terapeutico frente a la infeccion por leishmania y su uso.
US7541032B2 (en) 2002-09-20 2009-06-02 Stichting Katholieke Universiteit Antigen uptake receptor for Candida albicans on dendritic cells
AU2003278541A1 (en) * 2002-09-20 2004-04-08 Stichting Katholieke Universiteit Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
AU2003301804A1 (en) * 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
WO2004074432A2 (en) 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
AU2011211337B2 (en) * 2003-10-16 2014-10-02 Cancure Limited Immunomodulating compositions and uses therefor
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
AU2004299053B2 (en) * 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
DK1761248T3 (da) 2004-03-19 2012-09-03 Rodos Biotarget Gmbh Kulhydrat-deriverede liposomer bestemt til at målrettes mod cellulære kulhydrat-genkende-domæner af CTL/CTLD-lecitiner samt intracellulær afgivelse af terapeutisk aktive sammensætninger
US7884085B2 (en) * 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP1765294B1 (en) * 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
FR2895262B1 (fr) * 2005-12-22 2009-07-17 Lab Francais Du Fractionnement Inhibition de la reponse immunitaire anti-fviii
AT503387B1 (de) * 2006-03-27 2008-05-15 Univ Wien Pharmazeutische zusammensetzung zur vorbeugung von infektionen
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
EP2684889A3 (en) * 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
US8057798B2 (en) 2007-02-02 2011-11-15 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
EP2207798A2 (en) 2007-10-29 2010-07-21 Virginia Tech Intellectual Properties, Inc. Porcine dc-sign, icam-3 and lsectin and uses thereof
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2456786B2 (en) 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
EP2497498A4 (en) 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
JP5690132B2 (ja) 2010-06-17 2015-03-25 株式会社マーレ フィルターシステムズ エンジンの換気システム
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
MX364946B (es) * 2012-04-04 2019-05-15 Vaxform Llc Sistema adyuvante mejorado para la administración de vacunas orales.
US10196614B2 (en) * 2012-09-18 2019-02-05 University Of Washington Through Its Center For Commercialization Compositions and methods for antigen targeting to CD180
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
EP3318577A4 (en) 2015-06-30 2019-01-23 Osaka University ANTIPLEXIN A1 AGONISTANTIKÖRPER
CN108210503A (zh) * 2016-12-10 2018-06-29 高尚先 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US891992A (en) 1907-06-27 1908-06-30 Henry Hess Method of forming conically-shaped ends upon rollers and other objects.
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
IL102508A0 (en) * 1991-07-16 1993-01-14 Bristol Myers Squibb Co Inhibition of non-cd4 mediated hiv infection
AU7339294A (en) 1993-07-22 1995-02-20 Precision Valve Corporation Multi-directional actuation overcap
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1995032734A1 (en) 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US5548275A (en) * 1995-01-23 1996-08-20 Shambayati; Ali Alarm system for enclosing and protecting an area
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
WO1996023882A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US5871964A (en) * 1996-07-15 1999-02-16 Incyte Pharmaceuticals, Inc. Human C-type lectin
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
AU7172198A (en) * 1997-04-29 1998-11-24 Incyte Pharmaceuticals, Inc. Human c-type lectin
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US6273443B1 (en) * 1998-06-01 2001-08-14 Sunrise Medical Hhg Inc. Universal elevating leg rest assembly
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
EP1200590B1 (en) * 1999-08-12 2009-01-07 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US20040091481A1 (en) 2000-12-21 2004-05-13 Figdor Carl Gustav Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US20030232745A1 (en) 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) * 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2005057996A2 (en) * 2003-12-09 2005-06-23 Synergy Microwave Corporation User-definable thermal drift voltage control oscillator

Also Published As

Publication number Publication date
KR100923340B1 (ko) 2009-10-22
ATE398140T1 (de) 2008-07-15
US20050220804A1 (en) 2005-10-06
US8058400B2 (en) 2011-11-15
HK1036285A1 (en) 2001-12-28
NZ508723A (en) 2003-12-19
CA2330231C (en) 2013-07-16
US20080160041A1 (en) 2008-07-03
EP1516881A3 (en) 2005-08-31
WO2000063251A1 (en) 2000-10-26
JP5363432B2 (ja) 2013-12-11
DE60044621D1 (de) 2010-08-12
US7285642B2 (en) 2007-10-23
KR100952883B1 (ko) 2010-04-16
KR20010071530A (ko) 2001-07-28
EP1086137B1 (en) 2008-06-11
US8105599B2 (en) 2012-01-31
PT1086137E (pt) 2008-09-09
US20050118168A1 (en) 2005-06-02
EP1516881B1 (en) 2010-06-30
EP1046651A1 (en) 2000-10-25
CA2330231A1 (en) 2000-10-26
JP2003502283A (ja) 2003-01-21
EP1086137A1 (en) 2001-03-28
ES2307502T3 (es) 2008-12-01
DK1086137T3 (da) 2008-10-27
US7148329B1 (en) 2006-12-12
AU776317B2 (en) 2004-09-02
AU4152600A (en) 2000-11-02
JP4989820B2 (ja) 2012-08-01
JP2010285450A (ja) 2010-12-24
ES2346877T3 (es) 2010-10-21
KR20080098678A (ko) 2008-11-11
KR20070094990A (ko) 2007-09-27
ATE472558T1 (de) 2010-07-15
PT1516881E (pt) 2010-08-25
EP1516881A2 (en) 2005-03-23
DK1516881T3 (da) 2010-09-27

Similar Documents

Publication Publication Date Title
ATE398140T1 (de) Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen
AU2023200440B2 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP6998763B2 (ja) Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体
CN108431210B (zh) 培养细胞的方法及用于该方法的试剂盒和设备
CN113527521A (zh) 一种抗b7h3嵌合抗原受体及其应用
MX2012012833A (es) Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
KR20180099641A (ko) 세포의 배양 방법 및 이를 위한 키트와 장치
KR20190016966A (ko) 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
TW202313671A (zh) 嵌合抗原和ｔ細胞受體及使用方法
JP2021098708A (ja) シンデカン−２のモジュレーターとその使用
CN106999556A (zh) 细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗
CA3160609A1 (en) Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof
CA3178806A1 (en) Immune cells with enhanced function
Bezverbnaya et al. Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma
US12577534B2 (en) Transduction and expansion of cells
US12221480B2 (en) Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof
Battin et al. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents
CN121003685A (zh) 博来霉素作为免疫增强剂的用途
CN119215188A (zh) 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途
IL311901A (en) Multiple specific binding agents against PD-L1 and CD137 in combination therapy
CN119280420B (zh) 多特异性偶联物及其应用
WO2025261427A1 (zh) 用于评估抗体免疫激动剂偶联物产生ada的方法及其应用
HK40120568B (en) Multispecific conjugates and their applications
WO2023171009A1 (ja) Ｅｖａ１タンパク質に結合する、ヒト化抗体又はその機能的断片、抗体薬物複合体及びキメラ抗原受容体
Xie et al. cells inhibit the growth of solid tumors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition